At the time of writing, UroGen Pharma Ltd [URGN] stock is trading at $9.66, down -3.01%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The URGN shares have lost -9.13% over the last week, with a monthly amount drifted -2.62%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Guggenheim started tracking the stock with Buy rating on August 22, 2024, and set its price target to $40. On February 08, 2023, downgrade downgraded it’s rating to Hold and revised its price target to $10 on the stock. Berenberg started tracking the stock assigning a Buy rating and suggested a price target of $20 on April 27, 2022. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $57 on April 16, 2020. H.C. Wainwright reiterated a Buy rating for this stock on April 13, 2020, and downed its price target to $53. In a note dated January 09, 2020, National Securities initiated an Neutral rating and provided a target price of $37 on this stock.
For the past year, the stock price of UroGen Pharma Ltd fluctuated between $9.03 and $20.70. Currently, Wall Street analysts expect the stock to reach $25 within the next 12 months. UroGen Pharma Ltd [NASDAQ: URGN] shares were valued at $9.66 at the most recent close of the market. An investor can expect a potential return of 158.8% based on the average URGN price forecast.
Analyzing the URGN fundamentals
According to UroGen Pharma Ltd [NASDAQ:URGN], the company’s sales were 90.40M for trailing twelve months, which represents an 4.40% jump. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -1.07%, Pretax Profit Margin comes in at -1.37%, and Net Profit Margin reading is -1.4%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -73.64 and Total Capital is -0.4. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-14.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.30 points at the first support level, and at 8.93 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.26, and for the 2nd resistance point, it is at 10.85.
Ratios To Look Out For
It is important to note that UroGen Pharma Ltd [NASDAQ:URGN] has a current ratio of 6.01. Also, the Quick Ratio is 5.81, while the Cash Ratio stands at 3.74. Considering the valuation of this stock, the price to sales ratio is 4.93.
Transactions by insiders
Recent insider trading involved Schoenberg Mark, Chief Medical Officer, that happened on Jan 31 ’25 when 4551.0 shares were sold. General Counsel, Smith Jason Drew completed a deal on Jan 31 ’25 to sell 7379.0 shares. Meanwhile, Chief Medical Officer Schoenberg Mark sold 859.0 shares on Sep 09 ’24.
